Related Experiment Video
Updated: Sep 17, 2025
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Adjuvant Etoposide for Very High-risk PFA Ependymoma: A Case Report
Jacob Silverman1, Melissa Mégalli2, Emilie Giguère2
1McGill Faculty of Medicine and Health Sciences.
Background:
Ependymomas of the posterior fossa type A (PF-A) with a combined chromosome 1q gain and 6q loss are associated with an extremely high risk of recurrence and a very poor outcome.
Observations:
We report the case of a 4-year-old girl who received adjuvant oral etoposide for 1 year after conventional treatment (surgery and focal radiation). The patient remains in clinical and radiologic remission 2.5 years post-diagnosis.
Conclusions:
This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial.
